Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2021/11/17/2336301/0/en/OWP-Pharmaceuticals-Announces-IND-Authorization-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disorde.html
https://www.globenewswire.com/news-release/2021/07/01/2256446/0/en/OWP-Pharmaceuticals-Announces-Patent-Issuance-for-the-First-Ever-Oral-Liquid-Suspension-of-Quetiapine-for-the-Treatment-of-Schizophrenia-and-Bipolar-Disorder.html
https://www.globenewswire.com/news-release/2021/04/22/2215011/0/en/OWP-Pharmaceuticals-Announces-Patent-Application-for-the-First-Ever-Oral-Liquid-Formulation-of-Atomoxetine-Hydrochloride-for-the-Treatment-of-Attention-Deficit-Hyperactivity-Disord.html
https://www.biospace.com/article/releases/owp-pharmaceuticals-announces-ind-approval-for-the-first-ever-liquid-oral-suspension-formulation-of-quetiapine-fumarate-for-the-treatment-of-schizophrenia-and-bipolar-disorder/
https://www.globenewswire.com/news-release/2020/07/08/2059215/0/en/OWP-Pharmaceuticals-Announces-Patent-Application-for-the-First-Ever-Powder-for-Oral-Liquid-Formulation-of-Duloxetine-Hydrochloride-for-the-Treatment-of-Major-Depressive-and-General.html
https://www.globenewswire.com/news-release/2020/01/08/1967787/0/en/OWP-Pharmaceuticals-Announces-Pre-IND-Acknowledgement-and-Patent-Application-for-the-First-Ever-Liquid-Oral-Suspension-Formulation-of-Quetiapine-Fumarate-for-the-Treatment-of-Schiz.html
https://www.globenewswire.com/news-release/2020/01/08/1967787/0/en/OWP-Pharmaceuticals-Announces-Pre-IND-Acknowledgement-and-Patent-Application-for-the-First-Ever-Liquid-Oral-Suspension-Formulation-of-Quetiapine-Fumarate-for-the-Treatment-of-Schiz.html
https://www.globenewswire.com/news-release/2020/01/08/1967787/0/en/OWP-Pharmaceuticals-Announces-Pre-IND-Acknowledgement-and-Patent-Application-for-the-First-Ever-Liquid-Oral-Suspension-Formulation-of-Quetiapine-Fumarate-for-the-Treatment-of-Schiz.html